AZNAstraZenecaRunning, no new patients
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 142 (final count)
- Started
- Feb 22, 2024
- Main results expected
- Jan 12, 2026
- Fully finished
- Aug 27, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Resection rate
Measured over: At day of surgery (Within 40 days of the last dose of neoadjuvant treatment)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05925530 · record last updated 2026-09-09 · checked 2026-11-09 15:47 UTC